Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright has maintained a $3.00 price target for Cognition Therapeutics, Inc.